Parallel Advisors
OCUL icon

Parallel Advisors’s Ocular Therapeutix OCUL Stock Holding History

Parallel Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-82
Closed -$805 – 4117
2026
Q2 		$805 Buy
+82
New +$743 ﹤0.01% 3724
2025
Q1 		– Sell
-1
Closed -$9 – 3621
2024
Q4 		$9 Hold
1
– – ﹤0.01% 3505
2024
Q3 		$9 Buy
+1
New +$8 ﹤0.01% 3382
2022
Q1 		– Sell
-1,012
Closed -$7K – 3174
2021
Q4 		$7K Buy
+1,012
New +$7.86K ﹤0.01% 2268

Other funds holding OCUL

Deltec Asset Management
Deltec Asset Management New York $642M AUM 16.66% 1-Year Est. Return
Essex Investment Management
Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return
E. Ohman J:or Asset Management
E. Ohman J:or Asset Management Stockholm, Sweden $4.47B AUM 27.58% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return
Kraematon Investment Advisors
Kraematon Investment Advisors Braintree, Massachusetts $134M AUM 18.69% 1-Year Est. Return
Raiffeisen Bank International
Raiffeisen Bank International Vienna, Austria $8.69B AUM 38.11% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
Courier Capital
Courier Capital Buffalo, New York $2.02B AUM 16.74% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Parallel Advisors's OCUL Position: Q3 2026 in Review

Parallel Advisors sold out of Ocular Therapeutix (OCUL) in Q3 2026, closing a stake of 82 shares — an estimated $805 sold.

Parallel Advisors first reported a position in OCUL in Q4 2021 and held it in 4 quarters. The position peaked at $7K in Q4 2021. 61 funds tracked by Wall St. Rank hold OCUL as of Q3 2026.

  • Parallel Advisors reported no remaining Ocular Therapeutix position as of Q3 2026 after selling out during the quarter.
  • Parallel Advisors sold 82 Ocular Therapeutix shares in Q3 2026, an estimated $805.
  • Parallel Advisors first reported a position in Ocular Therapeutix in Q4 2021 and held it in 4 quarters.
  • Parallel Advisors's Ocular Therapeutix position peaked at $7K in Q4 2021.
  • 61 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2026.

Based on Parallel Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.